Rare Cause of Severe Hypertension in a Young Woman

Colin G. Perry, E. Marie Freel, Patrick O’Dwyer, Ernesto L. Schiffrin, Garry L. Jennings, Anna F. Dominiczak, Marc De Buyzere

Presentation of Case

An asymptomatic 20-year-old woman was seen at a preoperative assessment clinic before elective orthopedic surgery. She had a blood pressure of 240/110 mm Hg in both arms and was referred for urgent medical opinion. On examination, her phenotype was unremarkable. She had bilateral papilledema with normal cardiovascular examination other than her blood pressure. Renal function and urinalysis were normal.

The patient had a normal renal ultrasound, plain computed tomography of brain, and computed tomography cerebral venogram. Renin and aldosterone were normal with a normal ratio and potassium was within the normal range. She commenced amlopidine and an angiotensin-converting enzyme inhibitor with blood pressure falling to 151/112 mm Hg.

Dr Colin Perry: I would ask our experts, what would they do next?

Dr Ernesto Schiffrin: I think in a young person you have to consider secondary hypertension. And of course, with very severe elevated blood pressure I would have liked to know whether she is very pale, does she not have headaches? One would start to think of pheochromocytoma in a young person like this.

Dr Perry: That is why I think the history is very important at this stage, because she did not complain of recent headaches when seen initially in the emergency department. She was always rather pale.

Dr Schiffrin: I think that is important because I always tell the medical students that if the patient has a flushed face it is not pheochromocytoma. Pallor is almost an inevitable element.

Dr Marie Freel: Would there have been an argument that an MR angiogram of renal vessels might still have been appropriate in a young girl with malignant-phase hypertension because you can still have a fairly normal aldosterone renin ratio in that circumstance?

Dr Perry: I think that is entirely justifiable.

Discussion of Investigation

Dr Perry: Can I ask then, what test would you do for pheochromocytoma?

Dr Schiffrin: We usually measure urinary metanephrines.

Prof Garry Jennings: This lady did not have it, but when you have episodic hypertension with a pheochromocytoma, that is when your plasma measurement can be absolutely definitive. If they are not elevated and their blood pressure is up, they have not got a pheochromocytoma.

Dr. Schiffrin: Just going back to the history, simply because I have seen some of these patients, I would have inquired about family history, about thyroid surgery in the family.

Dr. Perry: I agree, however at this stage, she has not been to the specialist center. So, in fact you are correct. She does have headaches and if you really explore the history, she gives a good story of headaches. Eighty percent of patients with pheochromocytoma will give a history of headaches when asked specifically.

Twenty-four-hour urinary metanephrines and catecholamines were measured and were reported as elevated, with 24-hour urinary norepinephrine 11 374 nmol/24 hour (normal range <900 nmol/24 hour) and 24-hour urinary free normetanephrine 16 365 nmol/24 hour (normal range <650 nmol/24 hour).

Computed tomography scan of chest, abdomen, and pelvis revealed a left para-aortic mass and a smaller mass on the right, along with sclerotic vertebral and rib deposits (Figure 1).

123I metaiodobenzylguanidine (mIBG) scintigraphy confirmed widespread 123I mIBG avid disease (Figure 2).

Initial Management

Dr Perry: At this stage, what would you suggest in terms of treatment given the extensive nature of this young woman’s disease?

Dr. Schiffrin: Debulking.

Dr. Perry: Would anyone not operate at this point? Or do you think the right thing to do is to debulk as much disease as we can?

All heads nod.

After α- and β-blockade she underwent debulking surgery where a 80×40×22 mm tumor adjacent to left adrenal was resected along with affected lymph nodes.

Dr. Schiffrin: Perhaps for those who are not used to treating these patients, can you explain why you proceed with the phenoxybenzamine first and introduce the β-blocker shortly after?

Dr. Perry: So, the danger in a patient like this would be that if they are given unopposed β-blockade you may have profound α-mediated vasoconstriction and precipitate a crisis and that can be fatal. So, there is a real danger of giving the wrong agent in the wrong order. The options would be phenoxybenzamine and doxazosin. Phenoxybenzamine is long-acting and...
noncompetitive and is only inactive once the receptor becomes internalized. So that may be a safer approach to α-blockade preoperatively than doxazosin, although there are more symptoms associated with it and long-term phenoxybenzamine is not a particularly pleasant medication to take.

**Surgery Overview**

Prof Patrick O’Dwyer: We did a laparoscopic resection. We removed all her para-aortic and paracaval lymph nodes from the iliacs right up to the diaphragmatic crus, removing this, as you can see, with the vein. We divided the left renal vein. We removed it all laparoscopically and she was in hospital for 24 hours postoperatively with a noneventful recovery.

Dr. Schiffrin: During the manipulation of the tumor, were there any arrhythmias?

Prof O’Dwyer: No. We have done >100 pheochromocytomas or paragangliomas and we have not had a serious event in anyone. No arrhythmias. This is because the laparoscopy is so gentle on these tissues.

Prof Anna Dominiczak: Even in old times when we did open surgery, medically well-prepared patients, well α-blocked patients, did not have any tachycardias, arrhythmias, or blood pressure rises. Because if you give enough phenoxybenzamine nothing happens.

Prof. O’Dwyer: We did have 1 arrest, Anna, at open surgery on the table.

Prof Dominiczak: That was not my patient.

Pathological examination of the resected tumor revealed infiltrating islands of solid cellular sheets of tumor cells, which had round vesicular nuclei and eosinophilic granular cytoplasm. The tumor’s immunohistochemical staining was positive for chromogranin and synaptophysin. The Ki-67 proliferation index was variable, being <1% in some areas and between 2% and 3% in others. Infiltration into fat, vascular invasion, and involvement of local lymph nodes was evident.

**Postoperative Management**

The panel were asked about their suggestions for further treatment, with the patient having undergone debulking surgery though with disease still present.

Dr Schiffrin: mIBG treatment.

Dr Perry: Would anyone consider chemotherapy at this stage?

No response

Dr Perry: Would anyone watch and wait?

Heads shaking “No”

Since her surgery 20 months ago she has had 3 courses of 131I mIBG (10000 MBq on each occasion) and has tolerated this well, allowing her to return to her studies. Her disease is stable in terms of biochemistry and disease bulk, with most recent 24-hour urinary norepinephrine being recorded at 987 nmol/24 hour and 24-hour free normetanephrine 4198 nmol/24 hour. Despite there being no clear family history of neuroendocrine tumors, genetic testing revealed a pathogenic mutation in the succinate dehydrogenase B (SDHB) gene, which is predicted to affect the normal splicing of exon 1. This was later found in other members of her paternal family.

**Further Discussion**

Dr Schiffrin: I would like to hear a little bit more about genes and mutations and pheochromocytoma.

Dr Perry: I think it is important here to consider the approach to genetic testing. You may consider screening for most of the known genetic mutations, looking in particular for RET, SDHB, SDHD, von Hippel-Lindau (VHL); however in this patient I think you would predict that a mutation in the SDHB gene would be the most likely genetic predisposition to pheochromocytoma. This is based on her having abdominal disease with metastatic spread, rather than it being multicentric, and the biochemical phenotype was norepinephrine, rather than epinephrine, secreting. I think that takes you more toward an SDHB mutation than SDHD and away from RET; it is less likely to be a VHL mutation as there are no other associated features or relevant family history. As would be applicable to any other investigation, I think that there is value in identifying the most appropriate initial investigation, rather than a broad approach to screening for all the genetic mutations.
abnormalities. And if it were not a SDHB or SDHD mutation, you can start to think of other possibilities.

Dr Schiffrin: The association with thyroid cancer and the RET gene mutations?

Dr Perry: There was no history in the family or the patient to suggest multiple endocrine neoplasia type 2, or features of medullary thyroid cancer.

Dr Schiffrin: Is there any reason for looking at the arm-pits of patients who have pheochromocytoma or possible pheochromocytoma?

Dr Perry: It is always worth considering the phenotype of neurofibromatosis type 1 (NF-1), looking for café au lait patches and axillary freckling. NF-1 is very interesting because I think if you have NF-1 and a pheochromocytoma, the chance, we are told, of malignancy is higher than were it to be a sporadic pheochromocytoma. Perhaps as many as 6% of NF-1 patients develop pheochromocytomas, depending on which series you look at. The interesting question is how best to identify disease early; many NF-1 patients are only screened by asking them whether they have high blood pressure. That may not be sufficient.

Prof Dominiczak: I have an additional question. She is now 22. You have done debulking. You have done the treatment. She is likely to come to your clinic in a year or 2 to ask you, “Doctor, should I become pregnant?” What are you going to say?

Dr Perry: I think there is a danger in a future pregnancy and we would be concerned were she to plan this. We have had at least 1 VHL patient whose disease accelerated in the context of pregnancy. There would have to be a careful discussion of the associated risks.

Prof. Dominiczak: Another related question. We had a patient with this mutation discovered during her first pregnancy and this was a new mutation. This must be very rare in this genetic presentation. In your looking through the literature, have you seen many new mutations in SDHB?

Dr Perry: We have several families with the same SDHB mutation and the reason I think we are accumulating considerable experience locally is that we seem to have an SDHB founder mutation in the West of Scotland.

Mr Marc de Buyzere: In older literature, we learn when you have syndromic paragangliomas there was a kind of association possible with hemangiblastomas. Are there still arguments today that there is still an association?

Dr Perry: There is no doubt that carriers of the VHL mutation could develop both pheochromocytoma and hemangiblastoma. I have seen a similar presentation in a young man with VHL and bilateral pheochromocytoma and again a nor-epinephrine secreting phenotype in association with hemangiblastomas and renal cell carcinoma. There are of course also ocular manifestations. So, I think a full history is undoubtedly appropriate and in someone like this you may be guided toward the test for the most likely mutation.

**Overview**

Pheochromocytomas are tumors arising from the chromaffin cells of the adrenal medulla. Paragangliomas also arise from chromaffin cells but in extra-adrenal tissue, mainly along the sympathetic and parasympathetic chains. Both tumors are extremely rare; their combined incidence is ~8 per 100,000 patient years, whereas the prevalence of pheochromocytoma and paraganglioma in patients with hypertension in outpatient clinics varies between 0.2% and 0.6%. However, the incidence at postmortem is higher suggesting that these tumors are under diagnosed; undiagnosed tumors may be found in 0.05% to 0.1% of patients. A recent Endocrine Society Clinical Practice Guideline provided clear guidance on diagnosis and treatment of these rare tumors.

The majority of pheochromocytoma and paraganglioma are sporadic; however, a significant proportion arise because of underlying germline mutations. For example, recent studies estimate that between 30% to 50% of paragangliomas and up to 20% of pheochromocytomas may be associated with an inherited syndrome. Hereditary pheochromocytomas are associated with multiple endocrine neoplasia type 2, VHL syndrome, and NF-1. The estimated frequency of pheochromocytomas in these disorders is 10% to 20% in VHL, 50% in multiple endocrine neoplasia type 2, and 0.1% to 6% in NF-1. Hereditary paragangliomas are most often associated with mutations in genes encoding or stabilizing the SDH enzyme complex (SDHB, SDHD, SDHC, and SDHA), which forms the mitochondrial complex 2 and links the Krebs cycle to electron transport, whereas mutations in other genes that have been identified as predisposing to pheochromocytoma and paraganglioma include SDHAF2, MAX, and TMEM127.

Overall, the risk of malignancy, defined as the presence of metastases in nonchromaffin tissue, is relatively low, with prevalence between 10% and 17%. The incidence of malignancy in patients with mutations in the B subunit of SDH is reported as 17%, with disease presenting most often as abdominal norepinephrine-secreting paraganglioma; SDHD mutations are more frequently manifest as multifocal paraganglioma, often in the head and neck, and may be less frequently associated with malignancy.

Management in such cases is challenging and there is limited clinical trial evidence to support the value of therapeutic interventions such as 111 mIBG. A recent meta-analysis of the efficacy of 111 mIBG in metastatic pheochromocytoma found values for complete response, partial response, and stable disease of 0.02, 0.27, and 0.41 for tumor volume and of 0.10, 0.43, and 0.12 for biochemical response. There are, however, no large randomized controlled trial data to support its efficacy. Chemotherapy may also be considered in the form of cyclophosphamide, vincristine, and dacarbazine, with a trial of 18 patients finding complete response in 11% and a more recent meta-analysis suggesting partial response in terms of tumor volume and catecholamine excess of ≈40%. There is now early experience of tyrosine kinase inhibitors such as sunitinib in the treatment of metastatic disease. The First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (FIRSTMAPP) is a randomized, double-blind, multicenter study, which aims to determine the efficacy of treatment with sunitinib in patients with malignant pheochromocytoma.

Prognosis in patients presenting with malignant disease is variable. The overall 5-year survival may be <50%; however, the rate of progression of disease is unpredictable; Hescot et al demonstrated a 50% progression-free survival at 1 year.
in asymptomatic patients presenting with metastatic pheochromocytoma who received no treatment.

Here, we describe a young woman who presented with metastatic paraganglioma in the context of an SDHB mutation, but who has responded well to a combination of debulking surgery and repeated doses of 131I mIBG. Future therapeutic options include further 131I mIBG therapy, combination chemotherapy, or experimental treatments (eg, Sunitinib); however, none will afford the possibility of cure and will require careful consideration of risks versus benefits.

Acknowledgments
We thank Dr Lorna Cooper (Department of Pathology, Southern General Hospital, Glasgow, UK) for provision of histology slides.

Disclosures
None.

References
Rare Cause of Severe Hypertension in a Young Woman
Colin G. Perry, E. Marie Freel, Patrick O'Dwyer, Ernesto L. Schiffrin, Garry L. Jennings, Anna F. Dominiczak and Marc De Buyzere

Hypertension. 2015;65:21-24; originally published online November 10, 2014; doi: 10.1161/HYPERTENSIONAHA.114.04619
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/65/1/21

Data Supplement (unedited) at:
http://hyper.ahajournals.org/content/suppl/2015/01/09/HYPERTENSIONAHA.114.04619.DC1
http://hyper.ahajournals.org/content/suppl/2016/04/11/HYPERTENSIONAHA.114.04619.DC2

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org/subscriptions/
Rare Cause of Severe Hypertension in a Young Woman

Colin G. Perry, E. Marie Freel, Patrick O’Dwyer, Ernesto L. Schiffrin, Garry L. Jennings, Anna F. Dominiczak, Marc De Buyzere

初少莉 审校

病例介绍

患者，女性，20岁，无症状，拟行择期骨科手术，前来接受术前临床评估。测双上肢血压为240/110 mmHg，并行急诊会诊。经检查患者无明显的临床表现。除血压外，心血管系统检查及肾功能和尿液分析均正常，但可见双侧视乳头水肿。

该患者肾脏超声、脑血供计算机断层扫描（Computed tomography, CT）和脑CT静脉造影未见异常。肾素、醛固酮水平以及醛固酮/肾素比值和血钾均正常。患者开始氯沙坦平和血管紧张素转换酶抑制剂治疗，血压降至151/112 mmHg。

Colin Perry博士：我想询问各位专家，下一步该怎么做？

Ernesto Schiffrin博士：我认为对于年轻患者，必须要考虑继发性高血压。当然，该患者血压持续升高，我想知道患者是否有高血糖？对于类风湿关节炎的患者，开始就会想到是嗜铬细胞瘤。

Perry博士：这就是为什么我认为在这一阶段，病史非常重要。因为，患者在急诊室首次访时，并无近期头痛的主诉，但患者一直面色苍白。

Schiffrin博士：我认为这很重要。所以我向同学们强调，患者面色苍白，就不像嗜铬细胞瘤。面色苍白几乎不是嗜铬细胞瘤必备的表现。

Marie Freel博士：尽管醛固酮/肾素比值正常，但对于恶性高血压的年轻女性，是否需要行肾血管的核磁共振血管造影仍有争议。

Perry博士：我认为行肾血管的核磁共振血管造影完全合理。

有关检查的讨论

Perry博士：请问你们会做哪些嗜铬细胞瘤的检查？

Schiffrin博士：我们会做血尿素氮的甲氧基肾上腺素。

Garry Jennings博士：这位患者未做这项检查，因嗜铬细胞瘤的患者，当血压降低性升高时，测定血尿素氮即可确诊，如果血压升高时，甲氧基肾上腺素不高。则不像嗜铬细胞瘤。

Schiffrin博士：再去问一问患者，当敌友这样一些患者时，我会询问家族史，询问有无甲状腺家族性。

Perry博士：没错，不过在这个阶段，该患者还未到专科中心就诊。所以，你说得很对，实际上该患者有头痛史，如果你仔细追问，她会讲头痛的病史。如果认真问诊，80%的嗜铬细胞瘤有头痛病史。

该患者24小时尿甲氧基肾上腺素和儿茶酚胺升高。尿去甲肾上腺素水平为11,374 nmol/24 h（正常值为<900 nmol/24 h），尿去氧肾上腺素水平为16,365 nmol/24 h（正常值为<650 nmol/24 h）。

胸部、腹部和盆腔CT显示左侧主动脉旁可见一肿块，右侧亦有一小肿块（有关于椎体硬化和肋骨钙化沉积）（图1）。123I碘间碘苄胍（metaiodobenzylguanidine, mIBG）闪烁扫描证实存在广泛的123I碘mIBG摄取性病灶（图2）。

初始治疗

Perry博士：在这个阶段，考虑到这位年轻女性病史广泛，治疗上您有哪些建议？

Schiffrin博士：切除病灶。

Perry博士：有人认为此时不需要手术吗？或者你们认为正确的做法是尽可能地切除病灶。

大家均点头表示赞同。

在接受α和β阻滞剂治疗后，该患者接受切除手术，切
图1. 胸腹部和盆腔的计算机断层扫描（CT）提示左侧和右侧主动脉旁肿块。

除靠近左侧肾上腺的80×40×22 mm的肿块，同时切除受累及的淋巴结。

Schiffrin博士：对于那些不经常治疗这样患者的医生，您能否解释一下为什么首先给予苯氧丙胺治疗，随后才开始应用β受体阻滞剂?

Perry博士：因为，此类患者的危险在于，β受体阻滞剂在无拮抗情况下使用，则可能出现严重的α受体介导的血管收缩，促发危象，甚至可能致命。因此，真正的危险是以错误的顺序、使用错误的药物治疗，可以避免苯氧丙胺和多沙唑嗪。苯氧丙胺是一种长效的，非竞争性的药物，只有在受体内化后，才失去活性。因此，尽管服用苯氧丙胺后相关症状较多，而且，长期服用也非令人愉快，但术前应用该药比多沙唑嗪更安全。

手术概况

Patrick O’Dwyer教授：我们进行腹腔镜切除手术。切除患者主动脉旁的全部病灶和下腔静脉结和淋巴结，从髂骨直至髂肌脚，直到静脉，正如大家所见，分离了左侧肾静脉，通过腹腔镜切除了所有的淋巴结。该患者术后住院24小时，恢复顺利。

Schiffrin博士：在切除肿瘤的过程中，患者是否出现过心律失常?

Patrick O’Dwyer教授：没有。我们已经开展了100多例嗜铬细胞瘤或副神经节瘤手术，均未发生任何严重事件。没有发生心律失常，这是因为腹腔镜手术对这些组织影响很小。

Anna Dominiczak教授：即使在过去的手术中，术前准备良好的α-受体阻滞充分的患者，也不会发生心动过速，心律失常或血压升高。如果苯氧丙胺使用足够，就不会发生任何异常。

O’Dwyer教授：安娜，我们的确有一例患者，在开放手术的过程中发生心脏骤停。

Dominiczak教授：那不是我的患者。

对切除肿瘤的病理学检查显示浸润性的、实体性团块状肿瘤细胞，核呈圆形泡状，胞浆中有嗜酸颗粒。肿瘤的免疫组化染色显示嗜铬细胞和交感神经型。Ki-67增生指数不一致，一些区域<1%，一些区域为2%~3%。脂肪、血管侵润，局部淋巴结明显受累。

术后治疗

患者已接受肿瘤切除术，但疾病依然存在，因此，询问在座专家对该患者的进一步治疗有哪些建议。

Schiffrin博士：mIBG治疗。

Perry博士：有人认为在这个阶段需要进行化疗吗?

无人回应。

Perry博士：有人认为应该观察和等待吗?

大家摇头表示“不”。

该患者自从20个月前接受手术以来，共进行3个疗程的¹³¹碘mIBG治疗[每次治疗剂量10,000毫贝克（MBq）]，耐受性良好，使她能够重回她的研究工作中。根据生化指标和病灶情况，提示患者病情稳定。在最近测定的尿去甲肾上腺素为987 nmol/24 h，游离甲氧基去甲肾上腺素为1949 nmol/24 h。尽管患者无明确的神经内分泌家族史，但是，遗传学检测发现琥珀酸脱氢酶B（succinate dehydrogenase B，SDHB）基因存在病理性突变，推测该突变会影响到外显子1的正常剪切。后来，在她父系家族的其他成员中检出该突变。

图2. ¹³¹碘间碘苄胍闪烁扫描显示广泛性¹³¹碘间碘苄胍高摄取性病变。
进一步的讨论

Schiffrin博士：我想多了解一点关于基因突变和嗜铬细胞瘤。

Perry博士：我认为在这里讨论一下基因检测的方法是很重要的。你可以考虑筛查大多数已知的基因突变，尤其是检测RET，SDHB，SDHD和von Hippel-Lindau (VHL) 基因的突变。但是，我认为对于这位患者，你应当预测到SDHBD基因突变是嗜铬细胞瘤最常见的遗传易感因素。这是基于患者有腹部的广泛转移，而不是多灶性疾病；生化表型是分泌去甲肾上腺素，而不是肾上腺素。我想，这些都使你更多地去考虑是SDHBD突变，而不是SDHD突变，更不是RET突变，也不是可能是VHL突变，因为没有相关的症状及家族史。在任何其他筛查也适用时，我认为确定最具诊断基因很重要，而不是进行地筛查所有遗传异常。如果没有SDHB或SDHD突变，你再开始考虑其他可能性。

Schiffrin博士：甲状腺癌与RET基因突变的关系？

Perry博士：该患者没有多发性内分泌腺体2型的病史及家族史，亦无甲状腺癌样癌的病史。

Schiffrin博士：有理由检查嗜铬细胞瘤或是嗜铬细胞瘤患者的腋下吗？

Perry博士：值得考虑神经纤维瘤病1型（neurofibromatosis type 1, NF-1）的表型，看一看是否和咖啡牛奶斑或皮肤纤维瘤。NF-1非常有意思的，因为，如果同时患有NF-1和嗜铬细胞瘤，其恶性的可能性要高于散发的嗜铬细胞瘤。可能多达6%的NF-1患者发生嗜铬细胞瘤，这取决于你所观察的系列。令人感兴趣的问题是如何更早期地识别疾病，对很多NF-1患者的重要筛查是询问他们是否有高血压，这可能远远不够。

Dominiczak教授：我还有一个问题。该患者22岁，肿瘤已切除，也接受其它治疗。患者可能在一年内来到诊室询问：“医生，我能怀孕吗？”你如何回答？

Perry博士：我认为，未来有怀孕的风险。我们会关注她是否打算怀孕。我们至少碰到过一位VHL突变的患者在妊娠过程中病情恶化，因此，必须仔细讨论相关风险。

Dominiczak教授：另一个相关问题。我们有一例患者，在她初次妊娠时发现突变，且这是一个新的突变点，其遗传学表现非常罕见。如果查阅文献，您是否看到许多SDHB基因的新突变点？

Perry博士：我们有几个同是SDHB基因突变的家系。我认为，我们之所以在当地积累相当多的经验，是在于评估这种SDHB基因新的突变点。

Marc de Buyzere先生：在更早的文献中，我们了解到，当有副肿瘤症状时，会与血糖紊乱有关。最近，对于副肿瘤在妊娠有新的进展吗？

Perry博士：毫无疑问，VHL突变携带者会发生嗜铬细胞瘤和血管母细胞瘤。我见过报告表现，一位VHL基因突变的年轻男性患者，双侧嗜铬细胞瘤，去甲肾上腺素分泌型，同时伴有血管母细胞瘤和腿肿疾病。当然，还有肢体表现。因此，我认为完整的病史是必要的，和这样的患者，病史可能会指导你检测最有可能的突变。

总结

嗜铬细胞瘤是起源于肾上腺髓质嗜铬细胞的肿瘤。副神经节癌也起源于嗜铬细胞，但位于肾上腺以外的组织，主要沿交感和副交感神经连分布。这两种肿瘤非常罕见，其发病率大约为8/100,000患者年[13]，而副神经节癌的发病率约为0.2%~0.6%不等[14]。然而，尸检显示患者患病率更高，可能有0.05%~0.1%的患者未被诊断[15]。最近的分子学临床实践指南对这两种罕见肿瘤的诊断和治疗提出明确的指导意见[16]。

大多数嗜铬细胞瘤和副神经节癌是散发性的，但很大一部分肿瘤源于潜在的胚胎突变。例如，近期的研究估计大约30%~50%的副神经节癌和多达20%的嗜铬细胞瘤可能有遗传综合征[17]。遗传性嗜铬细胞瘤可能与多发性内分泌腺体2型，VHL综合征和NF-1有关。估计嗜铬细胞瘤的发生率在VHL为10%~20%，多发性内分泌腺体2型为50%，NF-1为1.5%~6%[10,11]。遗传性副神经节癌最常见的SDH复合物（SDHB，SDHD，SDHC和SDHA）编码或稳定基因的突变，SDH复合物构成线粒体复合物2，并连接三羧酸循环和电子传递[12]，而影响的是其它与嗜铬细胞瘤和副神经节癌易感性的相关的突变基因包括SDHAF2, MAX和TMEM127[13]。

总体来看，这些肿瘤的恶性程度（定义为具有非螺旋组织的转移）比较低。其发生率为10%~17%[14]。据报道，SDHB基因B亚单位突变的患者，恶性肿瘤比例为17%，最常见的表现为腹部肿瘤和去甲肾上腺素的副神经节瘤，SDHD突变更常见表现为多发性的副神经节瘤，通常见于头部和颈部，可能恶性少见[19]。

此类疾病的治疗具有挑战性，支持131碘mIBG等肿瘤干预治疗价值的临床证据有限。最近，一项131碘mIBG治疗转移性嗜铬细胞瘤疗效的荟萃分析，结果显示该治疗很有价值，依据肿瘤体积指标，完全缓解，部分缓解和疾病稳定的比例分别为0.02，0.27和0.41。依据生存指标，完全缓解，部分缓解和疾病稳定的比例分别为0.10，0.43和0.12[21]。不过，还没有大型随机、对照试验的数据支持131碘mIBG的疗效。化疗可以考虑使用环磷酰胺，长春新碱和达卡巴嗪。一项纳入18例患者的试验发现化疗的完全缓解率为11%[22]，新近开展的一项荟萃分析提示，依据肿瘤体积和肿瘤球状异常指标，部分缓解率为40%[23]。现有舒尼替尼等多靶点酪酸激酶抑制剂治疗恶性嗜铬细胞瘤和副神经节癌的初步
Experience. 嘌呤细胞瘤和副神经节瘤恶性进展的首个国际随机试验（First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma, FIRSTMAPP）是一项随机、双盲、多中心研究，旨在明确恶性嗜铬细胞瘤患者应用舒尼替尼的疗效。

恶性嗜铬细胞瘤和副神经节瘤患者的预后并不一致。五年总生存率可能低于50%；不过，疾病发展速度无法预测。Hescox等[37]证实，未经治疗的无症状的转移性嗜铬细胞瘤患者，一年无进展生存率为50%。

本文介绍一例有SDHB突变、表现为转移性副神经节瘤的女性患者，其对肿瘤切除术联合重复剂量的131I碘MBG治疗，反应良好。未来的治疗选择，包括进一步的131I碘MBG治疗，联合化疗或试验性治疗（如舒尼替尼），但是，没有治愈的可能性，并需要仔细权衡治疗的风险和获益。

致谢

我们感谢Lorna Cooper博士（英国格拉斯格南部总医院病理科）提供组织切片。

利益声明

无。

参考文献